Organoid research has rapidly advanced as a transformative platform for modeling development, disease, and regeneration, yet inconsistent reporting has hindered reproducibility and limited data integration across laboratories. The newly introduced Minimum Information about Organoid Research (MIOR) framework establishes a comprehensive, modular reporting system designed to address these challenges. MIOR defines clear requirements for project metadata, biological sources, organoid characterization, culture conditions, engineering strategies, and assay parameters. By distinguishing essential from recommended fields, the framework balances rigor with practical usability. MIOR aims to turn organoid datasets into reusable, comparable resources and strengthen the reliability and translational potential of organoid-based research.

Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced its participation in NeurIPS 2025, to be held in San Diego, USA, from December 2–7, 2025. Led by Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Petrina Kamya, PhD, Global Head of AI Platforms, Insilico’s experienced team will participate in the conference.

The electrocatalytic CO₂ reduction reaction (CO₂RR) serves as an effective approach to convert CO₂ into high-value chemicals and facilitate carbon cycling. Among various products, ethylene (C₂H₄), a crucial industrial feedstock, demonstrates substantial market demand and economic significance. Copper (Cu)-based catalysts exhibit remarkable advantages in CO₂RR to C₂H₄ conversion due to their unique electronic structure and optimal *CO adsorption capacity.

Concurrently, the membrane electrode assembly (MEA) design featuring an electrolyte-free cathode effectively addresses mass transfer limitations, minimizes ohmic losses, and enhances interfacial efficiency, thereby significantly boosting current density and product selectivity. The integration of Cu-based catalysts with MEA technology thus emerges as a highly promising solution for industrial-scale CO₂RR to C₂H₄ production.

In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2, which employs a dual mechanism of action—inducing PKMYT1 degradation while directly inhibiting its kinase activity. This innovative strategy holds promise for overcoming limitations of existing inhibitors, such as poor selectivity and acquired resistance, and to effectively target both the catalytic and non-catalytic functions of PKMYT1. As a result, the PROTAC demonstrates the potential for a more selective, potent, and durable therapeutic effect.

An international research team led by RMIT University have created tiny particles, known as nanodots, made from a metallic compound that can kill cancer cells while leaving healthy cells largely unharmed.

While this work is still at the cell-culture stage – it hasn’t been tested in animals or people – it points to a new strategy for designing cancer treatments that exploit cancer’s own weaknesses.

How far is it really from Hamburg to Rome – by ship, train, or truck? A research team including KLU Professor Arne Heinold has found a way to answer that question within milliseconds using open data. Their work was awarded the 2025 Prize for Open Data from the renowned American research institute, the Massachusetts Institute of Technology (MIT).